Bayer instigates Florbetaben trial

Bayer has revealed that it has instigated a study into its Alzheimer’s disease diagnostic therapy Florbetaben.

The international clinical trial aims to evaluate the efficacy and safety of florbetaben (BAY 94-9172) PET imaging in the detection of beta-Amyloid deposition in the brain.

Patients with and without manifest dementia will be evaluated after the previous trial discovered that the drug successfully demonstrated its potential to detect beta-Amyloid deposition in the brain as a pathological symptom of the disease.

Dr Thomas Balzer, head of global clinical development diagnostic imaging at Bayer, stated: “The ability to image beta-Amyloid depositions already during life is expected to be beneficial for a better and earlier diagnosis of this devastating disease.”

Last week, Bayer highlighted the verdict of the Diabetes Research Institute in Munich, which recently published guidelines on the benefits of using self-monitoring instruments for blood glucose measuring, such as those provided by the firm.